The Glutamate Release Inhibitor Riluzole Decreases Migration, Invasion, and Proliferation of Melanoma Cells
Authors:
- 1 September 2010
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 130 (9) , 2240-2249
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Treatment for metastatic malignant melanoma: Old drugs and new strategiesCritical Reviews in Oncology/Hematology, 2010
- A Phase 0 Trial of Riluzole in Patients with Resectable Stage III and IV MelanomaClinical Cancer Research, 2009
- Cutaneous malignant melanoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-upAnnals of Oncology, 2009
- Metabotropic glutamate receptors (mGlus) and cellular transformationNeuropharmacology, 2008
- Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformationPigment Cell & Melanoma Research, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Metabotropic Glutamate Receptor 1 and Glutamate Signaling in Human MelanomaCancer Research, 2007
- Focal Adhesion Kinase Promotes the Aggressive Melanoma PhenotypeCancer Research, 2005
- New ideas for therapy in ALSAmyotrophic Lateral Sclerosis, 2005
- The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanomaFrontiers in Bioscience-Landmark, 2005